Compare TY & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TY | NRIX |
|---|---|---|
| Founded | 1929 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | N/A | 2020 |
| Metric | TY | NRIX |
|---|---|---|
| Price | $34.83 | $22.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $30.50 |
| AVG Volume (30 Days) | 34.4K | ★ 2.9M |
| Earning Date | 01-01-0001 | 04-08-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 4.78 | N/A |
| Revenue | N/A | ★ $76,987,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $48.05 |
| P/E Ratio | $7.29 | ★ N/A |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $30.53 | $8.20 |
| 52 Week High | $36.03 | $23.09 |
| Indicator | TY | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 48.98 | 76.33 |
| Support Level | $34.20 | $14.86 |
| Resistance Level | $34.79 | $22.50 |
| Average True Range (ATR) | 0.64 | 1.61 |
| MACD | -0.07 | 0.61 |
| Stochastic Oscillator | 28.68 | 80.60 |
Tri-Continental Corp is a closed-end management investment company. It invests to produce future growth of both capital and income while providing reasonable current income. The fund is divided into two equal segments namely, the equity segment uses quantitative models to select individual stocks whereas the Flexible capital income segment invests across a company's investable capital structure, including stocks, bonds, and convertible securities. The Fund invests in a range of sectors, which include consumer discretionary, consumer staples, energy, financials, healthcare, industrials, information technology, industrials, materials, real estate, telecommunication services, utilities, aerospace and defense, banking, chemicals, and others.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.